Abeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company co-headquartered in Cleveland and New York, has received a boost from federal regulators with respect to development of a therapy for a metabolic disorder.
The company announced in a news release on Thursday, April 4, that the U.S. Food and Drug Administration has granted Fast Track designation to ABO-101, which is Abeona’s one-time gene therapy for Sanfilippo syndrome type B, or MPS IIIB.
Click here to read the complete article.
Story excerpt provided by Crain’s Cleveland Business.
Originally published April 4, 2019.